|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Alexandre Loiseau Ph.D.||Co-Founder & Chairman||244,06k||N/D||N/D|
|Mr. Nicolas Bouvier||Interim Chief Exec. Officer||N/D||N/D||N/D|
|Ms. Shu-i Gautheron||Chief Financial Officer||N/D||N/D||N/D|
|Mr. John S. Soto||Chief Operating Officer||N/D||N/D||1964|
|Mr. Frederic Banegas Ph.D.||Chief Technology Officer||N/D||N/D||N/D|
|Mr. François Lacombe Ph.D.||Chief Scientific Officer||N/D||N/D||N/D|
|Mr. Bruno Villaret||Global Director of Sales||N/D||N/D||N/D|
|Mr. Daryl Donatelli||VP of Global Marketing & U.S. Sales||N/D||N/D||N/D|
|Ms. Aline Criton Ph.D.||Chief Clinical & Regulatory Affairs Officer||N/D||N/D||N/D|
Mauna Kea Technologies SA develops and markets medical devices in Europe, the Middle East, Africa, the United States, Latin America, and Asia. The company designs, develops, and markets tools to visualize and detect cell abnormalities in real time during standard gastrointestinal and pulmonary endoscopy procedures. Its flagship product is Cellvizio, a confocal miniprobe endomicroscopy system which provides physicians and researchers high-resolution images of tissues at the cellular level. The company was incorporated in 2000 and is headquartered in Paris, France.
L'ISS Governance QualityScore di Mauna Kea Technologies SA al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.